Skip to content

Study · Animal study (in vivo) · rat · 2000

3 results

Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.

Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R

Hormone research1 Jan 2000Cited by 17 (Europe PMC)

PMID11146367 (opens in a new tab)DOI10.1159/000053183 (opens in a new tab)PepBankPUB-11146367
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In obese Zucker rats, oral AOD9604 for 19 days reduced body weight gain by more than 50% compared with control.

    In plain wordsIn obese rats, oral AOD9604 for 19 days cut weight gain by more than half compared with control.

    Peptide
    AOD-9604
    Outcome
    DecreaseBody weight gain
    Study

    ratsn: not reported in source

    obese Zucker rats
    Comparator
    Control
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    500 microg/kg body weight daily · oral · 19 daysAs given in this study (rats).

    Measurements

    Body weight gain
    15.8 g
    AOD9604
    Body weight gain
    35.6 g
    control
    Reduction in body weight gain
    > 50%
    AOD9604 vs control

    Source sentences

    Summary
    Daily treatment with an oral dose of AOD9604 of 500 microg/kg body weight for 19 days reduced over 50% (15.8 +/- 0.6 vs. 35.6 +/- 0.8 g) body weight gain of the animals in comparison with the control.
    1 context sentence
    Summary · context
    A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (hGH) has been studied for its metabolic actions in obese Zucker rats.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In obese Zucker rats, adipose tissue from AOD9604-treated animals showed increased lipolytic activity.

    In plain wordsIn obese rats, fat tissue from AOD9604-treated animals broke down fat more.

    Peptide
    AOD-9604
    Outcome
    IncreaseAdipose tissue lipolytic activity
    Study

    ratsn: not reported in source

    obese Zucker rats
    Comparator
    Control
    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    500 microg/kg body weight daily · oral · 19 daysAs given in this study (rats).

    Source sentences

    Summary
    The adipose tissues of the AOD9604--treated animals were found to have an increase in lipolytic activity.
    1 context sentence
    Summary · context
    A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (hGH) has been studied for its metabolic actions in obese Zucker rats.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In obese Zucker rats, chronic AOD9604 showed no adverse effect on insulin sensitivity in euglycemic clamp tests, unlike intact hGH.

    In plain wordsIn obese rats, AOD9604 did not harm insulin sensitivity, unlike human growth hormone.

    Peptide
    AOD-9604
    Outcome
    No significant changeInsulin sensitivity
    Study

    ratsn: not reported in source

    obese Zucker rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    500 microg/kg body weight daily · oral · 19 daysAs given in this study (rats).

    Source sentences

    Summary
    In contrast to chronic treatment with intact hGH, chronic treatment with AOD9604 showed no adverse effect on insulin sensitivity of the animals, as demonstrated with euglycemic clamp techniques.
    1 context sentence
    Summary · context
    A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (hGH) has been studied for its metabolic actions in obese Zucker rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    9 Oct 2026, 18:17 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.